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 91 
Abstract: 92 
Background: The Clinical High Risk state for Psychosis (CHR-P) has become the cornerstone 93 
of modern preventive psychiatry. The next stage of clinical advancements rests on the ability 94 
to formulate a more accurate prognostic estimate at the individual subject level. Individual 95 
Participant Data Meta-Analyses (IPD-MA) are robust evidence synthesis methods that can also 96 
offer powerful approaches to the development and validation of personalized prognostic 97 
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models. The aim of the study was to develop and validate an individualized, clinically-based 98 
prognostic model for forecasting transition to psychosis from a CHR-P stage.  99 
Methods: A literature search was performed between January 30th 2016 and February 6th, 2016 100 
consulting PubMed, Psychinfo, Picarta, Embase and ISI Web of Science, using search terms 101 
("ultra high risk" OR "clinical high risk" OR "at risk mental state") AND ((conver* OR 102 
transition* OR onset OR emerg* OR develop*) AND psychosis) for both longitudinal and 103 
intervention CHR-P studies. Clinical knowledge was used to a priori select predictors: age, 104 
gender, CHR-P subgroup, the severity of attenuated positive psychotic symptoms, the severity 105 
of attenuated negative psychotic symptoms and level of functioning at baseline. The model thus 106 
developed was validated with an extended form of internal validation. 107 
Results: Fifteen of the 43 studies identified agreed to share IPD, for a total sample size of 1676. 108 
There was a high level of heterogeneity between the CHR-P studies with regard to inclusion 109 
criteria, type of assessment instruments, transition criteria, preventive treatment offered. The 110 
internally-validated prognostic performance of the model was higher than chance but only 111 
moderate (Harrell’s C-statistic 0.655, 95% CIs 0.627 - 0.682).  112 
Conclusion: This is the first IPD-MA conducted in the largest samples of CHR-P ever 113 
collected to date. An individualized prognostic model based on clinical predictors available in 114 
clinical routine was developed and internally validated, reaching only moderate prognostic 115 
performance. Although personalized risk prediction is of great value in the clinical practice, 116 
future developments are essential, including the refinement of the prognostic model and its 117 
external validation. However, because of the current high diagnostic, prognostic and 118 
therapeutic heterogeneity of CHR-P studies, IPD-MAs in this population may have an limited 119 
intrinsic power to deliver robust prognostic models.    120 
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INTRODUCTION 121 
Clinical research on early recognition and intervention of psychotic disorders has enormously 122 
expanded over the past two decades (1). There is converging evidence that individuals with an 123 
elevated risk for psychosis, commonly termed as at Clinical Risk for Psychosis (CHR-P) (or as 124 
‘Ultra High Risk’ (UHR) or ‘at‐risk mental state’ (ARMS)), can be identified prior to the onset 125 
of a psychotic episode. CHR-P criteria are based by the presence of attenuated psychotic 126 
symptoms, brief and intermittent psychotic symptoms with spontaneous remission, or genetic 127 
risk for psychosis (2–4), usually combined with functional impairments and help-seeking 128 
behaviour (5). CHR-P individuals accumulate several risk factors for psychosis (6) and have a 129 
meta-analytical risk of developing psychosis of 20% (95%-confidence interval of 17%-25%) at 130 
2-years (for details see Table 4 in Fusar-Poli et al. (7)) while they are not an increased risk for 131 
developing non-psychotic mental disorders (8). The level of risk for psychosis is highest in 132 
those with a short-lived psychotic episode, intermediate in those with attenuated positive 133 
psychotic symptoms and lowest in those at genetic risk (9). Overall, the meta-analytical 134 
prognostic performance of the CHR-P assessment is excellent (AUC of 0.9 at 38-months) (10) 135 
and comparable to that of prognostic models used in other branches of somatic medicine. 136 
Despite these achievements, to date, the formulation of a prognosis in CHR-P individuals has 137 
been limited to group-level predictions. In light of the recent emergence of precision medicine 138 
approaches, it is thus important to develop and validate prognostic models that can calculate a 139 
personalized risk rather than a group-level global risk estimate. Prognostic modelling combines 140 
multiple predictor variables with their relative weight to estimate the risk or probability that an 141 
outcome or specific event will occur in an individual patient (11) and is often used in medical 142 
sciences such as cardiology or oncology (e.g. (12,13). The calculated individual risks could then 143 
be utilized by the caregiver to inform treatment decisions.  144 
 145 
More recently, prognostic models have entered clinical psychiatry (for a methodological review 146 
see Fusar-Poli et al (14)). A systematic review has identified seven prognostic models for CHR-147 
P populations, most of which suffer from methodological weaknesses such as the use of 148 
suboptimal model building methods, small sample sizes and the lack of internal or external 149 
validation (15). Several recommendations for building robust prognostic models in CHR-P 150 
populations were made, including the use of large sample sizes, and appropriate events per 151 
variable ratios, the selection of a priori predictors on the basis of clinical knowledge or the use 152 
of automated selection features through machine-learning methods and the essential need to 153 
present validated (internal and external) measures of prognostic performance (14). Some 154 
examples of robust prognostic subject-level models for CHR-P populations include the NAPLS 155 
risk calculator by Cannon et al (16) (which has been externally validated (17)), the pretest risk 156 
enrichment stratification algorithm by Fusar-Poli et al (18) (which has been externally 157 
validated), the transdiagnostic risk calculator by Fusar-Poli et al (19) (which has been externally 158 
validated twice (20) and implemented in clinical routine (21)) and the functional outcome 159 
prognostic model by Koutsouleris et al (22) (internally validated). Yet, the key create-limiting 160 
step towards implementation of prognostic models into CHR-P clinical routine is the 161 
availability of predictors. Biological and neurophysiological data require more expensive and 162 
intrusive assessment methods which are not always available in clinical practice, limiting the 163 
clinical utility of these models. Rather, neurobiological-based prognostic models can further 164 
refine the prediction of outcomes when used in a stepped sequential framework (23), after 165 
simpler prognostic models are applied.  166 
 167 
We present here an innovative approach for developing risk prediction models for CHR-P 168 
individuals that are based on clinical predictors routinely collected as part of clinical practice. 169 
We developed a multivariable (i.e. including several predictors) risk estimation model through 170 
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re-analyzing original individual raw data, requested from systemically sought research groups 171 
(24), through an Individual Patient Data Meta-analysis (IPD-MA). Prognostic models 172 
developed from an IPD-MA offer several unexplored advantages such as large sample sizes, 173 
which are of core importance in the case of rare events such as the transition to psychosis from 174 
CHR-P stage (25). Moreover, because an IPD-MA leverages the variation in the characteristics 175 
of the CHR-P included, it can potentially increase the generalizability of the prognostic model. 176 
Furthermore, a prognostic model derived from IPD-MA can statistically take into account the 177 
differences in prognostic parameters (such as intercepts and predictor-outcome associations) 178 
across the included original studies and can explore under which circumstances the prognostic 179 
model predicts optimally (26). Despite these potentials, no IPD-MA has ever been conducted 180 
in the CHR-P field.  181 
 182 
The primary aim of the current study was to develop and validate an individualized, clinically-183 
based prognostic model for forecasting transition to psychosis from a CHR-P stage using 184 
predictors that were selected on the basis of a priori clinical knowledge and that were available 185 
in clinical routine.  186 
 187 
METHODS 188 
Search strategies 189 
A systematic search strategy was performed to identify relevant original studies. First, an 190 
electronic search was performed in PubMed, Psychinfo, Picarta, Embase and ISI Web of 191 
Science. The search was conducted between January 30th 2016 and February 6th, 2016. The 192 
following search terms were used: ("ultra high risk" OR "clinical high risk" OR "at risk 193 
mental state") AND ((conver* OR transition* OR onset OR emerg* OR develop*) AND 194 
psychosis). Second, the reference lists of the included articles were manually checked for 195 
studies not identified by the computerized search.  196 
 197 
Selection criteria  198 
Inclusion criteria were:  199 
(1) data reported in an original paper in a peer-reviewed journal; 200 
(2) involved CHR-P subjects 14-40 years old, defined according to established international 201 
criteria (1); 202 
(3) assessed attenuated positive and negative psychotic symptoms as well as level of 203 
functioning at baseline using standardized CHR-P measurements; 204 
(4) reported transition status at follow-up (events); 205 
(5) reported time to transition or time to last follow-up assessment.  206 
 207 
Both longitudinal and intervention studies were included. In the case of studies investigating 208 
heterogeneous patient populations, only CHR-P individuals were selected for the analysis. 209 
Furthermore, CHR-P individuals who were not meeting the age criterion defined above were 210 
excluded from the analysis, as well as CHR-P patients who were already psychotic at baseline 211 
as documented in the corresponding articles.   212 
To achieve a high standard of reporting, we adopted the Preferred Reporting Items for 213 
Systematic Reviews and Meta-analyses Guidelines - Individual Patient Data (PRISMA-IPD, 214 
(27) as well as the statement Transparent reporting of a multivariable prediction model for 215 
individual prognosis or diagnosis (TRIPOD) (28). The meta-analysis was registered in the 216 
PROSPERO database for systematic reviews and meta-analysis (CRD42017071176). 217 
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Selection of predictors  218 
For developing and validating a prediction model, it is recommended to select prognostic 219 
variables a priori based on earlier research (28) and clinical knowledge (14). In order to develop 220 
a model that is readily applicable in clinical practice, the selected predictors were limited to 221 
those routinely assessed in CHR-P clinics and involved demographical and clinical predictors. 222 
The a priori selected predictors were age, gender, CHR-P subgroup (attenuated psychotic 223 
symptoms, brief and limited intermittent psychotic symptoms, genetic risk and deterioration 224 
syndrome), baseline severity of attenuated positive and negative psychotic symptoms and level 225 
of functioning. The a priori clinical rationale for selecting these predictors is given below. The 226 
first predictor is age: in general, youth in their late teens and early twenties have the highest risk 227 
of developing psychosis (29) Kessler, et al, 2007), and a meta-analysis revealed that older CHR-228 
P individuals had a significant higher risk for developing a psychotic episode (30). Another 229 
recent umbrella review found that being aged 15-35 years is a strong factor associated with an 230 
increased risk of psychosis (31). The same umbrella review found that gender, the second 231 
predictor in our model, has a clear association with an increased risk of psychosis (31). In fact, 232 
gender has already been used as predictor in other prognostic models developed for CHR-P 233 
populations (19). The third predictor was the severity of attenuated positive psychotic 234 
symptoms such as delusions, unusual thought content and suspicion, which are the most studied 235 
and established predictors in CHR-P field, and already used by previous prognostic tools in this 236 
group (16). Furthermore, a recent meta-analysis of 33 studies, involving a total of 4227 CHR-237 
P individuals, showed different levels of the risk for psychosis onset,, where persons with brief 238 
and limited intermittent psychotic symptoms had the highest risk of transition, followed by 239 
those with attenuated positive psychotic symptoms, and by those with genetic risk and 240 
deterioration syndrome who had the lowest risk (9). Therefore, the CHR-P subgroups were 241 
included as three independent predictors, recording whether or not the criteria of each 242 
distinctive risk group were met. Attenuated negative psychotic symptoms encompass social 243 
amotivation (apathy, anhedonia, asociality) and expressive deficits (alogia, diminished 244 
emotional expression) (32) and were selected as the seventh predictor. Attenuated negative 245 
psychotic symptoms were predictive of a subsequent psychotic disorder in CHR-P individuals 246 
(33,34). The last predictor variable was the level of functioning at baseline: a meta-analysis in 247 
CHR-P individuals confirmed that functioning is a strong predictor of transition to psychosis 248 
(35). 249 
 250 
Data collection 251 
Abstracts were screened independently by two reviewers (AM and NB or MP). Each article was 252 
assessed individually, and any disagreements resolved by discussion with a third reviewer. 253 
Subsequently, all corresponding authors of the eligible studies identified were contacted to 254 
request anonymized individual patient data and regarded as non-responders when no reaction 255 
was received after two reminder emails.  256 
 257 
Data extraction 258 
From each individual patient, the following variables were included: gender, the baseline age 259 
of participant, CHR-P group, the severity of attenuated psychotic positive and negative 260 
symptoms, level of functioning, transition status at follow-up and duration of the follow-up 261 
period. To get a better understanding of possible factors that may have influenced the 262 
performance of the prognostic model across the different studies, as well as to detect factors 263 
that may have contributed to the study heterogeneity, we also collected for each study additional 264 
data. These data related to the inclusion period, inclusion strategies, in and exclusion criteria, 265 
the psychometric criteria employed to define transition to psychosis and the type of CHR-P 266 
assessment instruments (for a comparative analysis of CHR-P assessment instruments see 267 
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Fusar-Poli et al (36)), and the instruments applied to assess symptoms and functioning.    268 
 269 
Data storage 270 
All data was anonymized by the researchers of the original studies and therefore not re-271 
identifiable to an individual patient by the current investigators. All cleaned datasets were 272 
stored on a secured server in their original formats and converted to a master dataset. Data 273 
were inspected on unusual outliers via range check of the all included variables.  274 
 275 
Data transformation 276 
Studies vary in the CHR-P instruments assessing the severity of attenuate positive psychotic 277 
symptoms, attenuated negative psychotic symptoms, and functioning. Thus, to make it 278 
clinically applicable only one measurement was selected in the model as the primary parameter. 279 
The selection of the assessment measure was defined a priori on the basis of clinical reasoning.   280 
 281 
Missing data 282 
Missing data was imputed according to Multiple Imputations with Chained Equations (MICE) 283 
with 50 iterations sets. As recommended by White and Royston (37), the event indicator and 284 
Nelson-Aalen estimator of cumulative baseline hazard were included in the imputation model. 285 
Also, the study name of the original data was included as a dummy factor to account for 286 
potential between-study heterogeneity. Rubin’s Rules were applied to combine the data from 287 
the imputation sets (38).  288 
 289 
Risk of bias assessment in individual studies 290 
The assessment of the methodological quality of each individual included study is an essential 291 
element in meta-analyses (27). The majority of the studies in this IPD-MA have a naturalistic 292 
observational design (N=12). As such we used the systematic review of Zeng et al (39), which 293 
recommends the Newcastle-Ottawa Scale (NOS) (40), a nine-item scale categorized into three 294 
dimensions, namely selection, comparability and outcome. Quality assessment of naturalistic 295 
and observational studies in meta-analyses is problematic. In fact, the key components of 296 
studies to be assessed on the MOOSE’s recommendations were whether the outcome of interest 297 
was not present at the start of the study, the follow-up period of the study was long enough for 298 
the outcome to occur, and an adequate proportion of the subjects participated in the follow-up 299 
cohort (41). The minimal follow-up period in this IPD-MA was set at twelve months. Studies 300 
received a positive score for adequacy of follow-up cohort when they had a minimum follow-301 
up rate of 50-80% in cohort studies or 80% in RCTs (42).  302 
 303 
Primary outcome 304 
The primary outcome is the transition to psychosis (event) from a CHR-P stage. Transition to 305 
psychosis was defined according to the criteria of the Comprehensive Assessment of At Risk 306 
Mental State (CAARMS) (2), Structured Interview of Prodromal Symptoms/Scale of Prodromal 307 
Symptoms (SIPS/SOPS (3)), Brief Psychiatric Rating Scale (BPRS (43)), Positive And 308 
Negative Syndrome Scale (PANSS (44)) or Structured Interview for Diagnostic and Statistical 309 
Manual of Mental Disorders, fourth edition (SCID-IV (45)). CHR-P patient outcomes were 310 
recorded as transitioned to a psychosis, no transition or lost to follow-up.  311 
 312 
Data analyses 313 
Individuals with a complete follow-up assessment were compared to those lost to follow-up 314 
with an independent T-test (continuous variables) or Chi-square test (binary variables) for 315 
descriptive purposes. Collinearity of predictors was tested with the variance inflation factor 316 
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(VIF) and estimated by the formula 1/(1-R2). An outcome of 4 or lower indicates a low 317 
indication of collinearity between the predictors (46).  318 
A parametric survival model with a log-normal distribution for event times was computed 319 
(Royston, 2001). The evaluation of the model’s performance and generalizability was done with 320 
an extended form of internal validation, because of the lack of true external validation data. 321 
Therefore, an Internal-External Cross Validation technique (IECV) was applied, which 322 
maximized the data available for both model development as well as model validation (26). 323 
With the IECV, all studies (M) minus one study were used as a derivation set to develop a 324 
prediction model, and the remaining set is used for its external validation. This was repeated 325 
for each dataset, leading to M scenarios to investigate consistent model performance, which was 326 
combined by applying Rubin’s Rules (38). All discovered studies were utilized in the 327 
development and validation of the model. A t-test calculated the significance of the final beta 328 
coefficients of the predictors.   329 
The model performance was estimated by calculating its discrimination and calibration. 330 
Discrimination referred to the model’s ability to separate CHR-P individuals who transitioned 331 
to psychosis versus those who did not transition. For each study, a bar graph with the frequency 332 
distribution of predicted survival of the survival groups was presented, for both 12-months as 333 
well as 24-months. For both 12- and 24 months, the bar graph showed ten risk groups, which 334 
each represented an equal number of individuals. The distribution of the risk groups, which 335 
ranged from 0 (no chance of survival, i.e. transition to a psychosis) until 100 (100% chance of 336 
survival, so no transition to psychosis) was determined by the observed survival per study. A 337 
well-discriminating model shows a high overlap between the predicted survival and the 338 
observed survival in the different risk categories (48). Moreover, Harrell’s C-statistics with its 339 
95%-confidence intervals (CI) was calculated per study, which referred to the overall 340 
probability that the model estimates a higher risk for the CHR-P individual that does develop 341 
psychosis compared to a person that does not. Values of C-statistics higher than 0.5 (random 342 
prediction) and lower than 0.6 are considered “poor”, from 0.6 and 0.7 are considerate 343 
“moderate”, from 0.7 to 0.8 “adequate”, from 0.8 to 0.9 “excellent” and above 0.9 344 
“outstanding”, up to 1 (perfect prediction). The C-statistics of all individuals studies was plotted 345 
in a forest plot, with the 95%-CI indicating a possible statistical difference from random 346 
prediction. Furthermore, for each study, the calibration of the model was calculated, which 347 
referred to the agreement between the observed and the predicted outcomes (48) and was 348 
presented with its 95%-CI for each individual article in a forest plot. The linear predictor is 349 
calculated according to the coefficients of the model and included as a covariate in a Cox Model. 350 
The slope of the linear predictor is the calibration slope.  The calibration plot can be viewed as 351 
a measure of fit of the prognostic model in the CHR-P population: when a study’s 95%-CI 352 
included the value of 1 it indicated a fit, whereas a 95%-CI not containing a score of 1 implied 353 
a serious misfit of the model suggesting that adjustments of the model’s intercepts should be 354 
considered.   355 
CHR-P studies differed with regard to study design, inclusion period, recruitment strategies, 356 
inclusion and exclusion criteria, transition criteria, CHR-P assessment instruments and 357 
treatments offered. These characteristics were expected to influence the effects of the prognostic 358 
model in this IPD-MA. In meta-analyses, heterogeneity is examined with the Q-statistic and I2 359 
Index (24). However, in studies that develop prediction models based on IPD-MA, the extent 360 
of heterogeneity is better quantified by studying the 95% prediction intervals (50).  361 
 362 
All statistical analyses were conducted using R, version 4.2.2 (49) and used the following 363 
packages: foreign, mice, micemd, Hmsic, VIM, jomo, flexsurv, metamisc, rms, and pec.  364 
 365 
RESULTS 366 
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Studies and participants  367 
A total of 2176 papers was identified by the literature search and 43 were deemed eligible for 368 
the IPD-MA. The corresponding authors of the 43 studies were contacted, of which 15 agreed 369 
to participate and shared all necessary individual patient data needed for the model (see Figure 370 
1). Of the remaining authors seven authors replied to work on the same subject, two were not 371 
able to share the essential data and nineteen authors did not reply at all. These 28 studies related 372 
to a total of 2815 CHR-P individuals (62.7% of CHR-P eligible subjects), of whom 475 373 
transitioned to psychosis (16,9% of the eligible yet not included subjects). There is a selection 374 
bias in that the current IPD-MA included 1676 CHR-P individuals, of whom 386 developed 375 
psychosis. This corresponded to 37.3% of all the CHR-P eligible participants.  376 
The participating studies were Access, Detection And Psychosocial Treatment (ADAPT) (51), 377 
Clinic for Assessment of Youth at Risk (CAYR) (52), Dutch Prediction of Psychosis Study – 378 
Amsterdam (DUPS-A) (53), Early Detection and Intervention Evaluation – Netherlands (EDIE-379 
NL) (54), Early Detection and Intervention-United Kingdom (EDIE-UK) (55), Früherkennung 380 
von Psychosen (FePsy) (56),  Früherkennungs- und Therapiezentrum für psychische Krisen 381 
(FETZ) (57), Green Program for Recognition and Prevention of Early Psychosis (GRAPE) (58), 382 
Integrative Neuroimaging Studies in Schizophrenia Targeting for Early intervention and 383 
Prevention (IN-STEP) (59), Outreach and Support in South London (OASIS) (Fusar-Poli, et 384 
al., 2013), Personal Assessment and Crisis Evaluation (PACE) (61), Programme of Recognition 385 
and Therapy (PORT) (62), ROME (63), Sendai ARMS and First Episode clinic (SAFE) (64), 386 
and Dutch Prediction of Psychosis Study - Utrecht (DUPS-U) (65).  387 
[Figure 1 about here] 388 
Furthermore, for each included study we checked whether CHR-P individuals met the inclusion 389 
criteria. CHR-P individuals younger than 14 years were removed from the data set: ADAPT 390 
(N=2), CAYR (N=1), DUPS (N=4), EDIE-NL (N=1), PACE (N=1), Rome (N=19), and DUPS-391 
U (N=14), as well as participants of older than 40 years: FePsy (N=10) and IN-STEP (N=1). 392 
Subjects with an elevated risk for psychosis but not meeting the established CHR criteria were 393 
excluded: FePsy (n=30), FETZ (N=30), INSTEP (N=4), and DUPS-U (N=4). Similarly, 394 
subjects who were already psychotic as reported in the corresponding article were filtered out: 395 
EDIE-NL (psychotic at inclusion (N=4), history of psychosis (N=1)). Subjects’ data was 396 
censored to the primary study protocol stated follow-up period: FePsy (N=1) and CAYR (N=4). 397 
Because of these procedures, a final sample of 1676 individuals fulfilled the inclusion criteria 398 
and was included in the IPD-MA. Key details of the included studies are summarized in table 399 
1, more comprehensive information on each study is included in Supplement IV.  400 
[Table 1 about here] 401 
An overview of the comparison of study characteristics is presented in table 2. CHR-P studies 402 
worldwide participated in the study and the majority of studies took place in Europe (53–403 
57,60,62,63,65). Three studies concerned a Randomized Controlled Trial (RCT) (51,54,55), 404 
one study had a mixed design of both RCT and naturalistic observational design (61), while all 405 
the others had a naturalistic observational design. The earlier studies started including 406 
individuals in 1993 (61), while the later studies started including in 2013 (60). The inclusion 407 
period varied between one year (52) until thirteen years (61). The smallest study contained 408 
nineteen subjects (63), while the largest study contained over 400 individuals (61). Despite 409 
methodological differences, one inclusion criterion was shared by all studies, namely meeting 410 
the clinical high risk criteria of at least one of the high risk groups (GRD, APS, or BLIPS). 411 
Eleven studies had additional age criteria  (52,54,55,58–64), one study included only 412 
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participants with a minimum of nine years of education (58) and another study had as additional 413 
criterion that individuals should have no history of antipsychotic medication for over 16 weeks 414 
(59). There was a greater variety in the applied exclusion criteria, with only the EDIE-UK (55) 415 
study that did not exclude subjects in case of a known organic cause for the presentation of 416 
prodromal symptoms. Twelve studies excluded individuals with both a current or a lifetime 417 
psychotic condition(51,54,58,60–68). Ten studies excluded individuals with lower intellectual 418 
capacities (51,52,54,56,57,59,60,62,64,65), five studies excluded individuals in case of 419 
substance use or abuse (52,59,60,63,64). Current or a history of antipsychotic medication was 420 
an exclusion criterion in six studies. Two studies excluded individuals with insufficient 421 
competence of the primary language (54,66). The presence of a pervasive developmental or 422 
autism spectrum disorder was an exclusion criterion in two studies (52,59). In one study, a 423 
history of electroshock therapy (59), withdrawing their willingness to be followed by the service 424 
(60) or suicide risk due to personality disorder (64) was an exclusion criterion. In the final 425 
database, the mean follow-up time was of 32.37 months (SD=31.59) and there were 386 426 
transitions to psychosis (events) (23.0%). Therefore the final Event Per Variable ratio was 1:48, 427 
which is below the threshold recommended for building robust prognostic models (14).   428 
Eight out of fifteen studies launched special information campaigns, either targeting only 429 
potential sources of participant referrals or the general public (51,52,55,60,62,64,66,67). The 430 
campaigns differed in their elaborateness: from a website and folders to workshops, letters in 431 
newspapers and advertisement on radio and television. All studies included individuals that 432 
were referred to them, but a few studies combined this with the option of self-referral (52,62), 433 
referral by a close friend or family member (52) or screening in a help seeking population (54). 434 
Six studies offered additional treatment such as case management, cognitive behavioural 435 
therapy, psychoeducation for the CHR individuals as well as for family, medication, sport and 436 
nutrition groups (52,60–62,64,66). Information on specific treatments that were offered was 437 
only available for RCTs; most studies did not keep detailed records of offered interventions.   438 
With regard to the assessment of CHR-P, symptoms and functioning, four instruments were 439 
applied to determine whether an individual met the CHR criteria, namely PANSS (44), 440 
CAARMS (2), the Basel Screening Instrument for Psychosis (BSIP) (4) and the SIPS/SOPS 441 
(3). Positive psychotic symptoms were assessed with five different instruments: PANSS (44), 442 
CAARMS (2), BPRS (43), SIPS (69), and the Scale of Assessment of Positive Symptoms 443 
(SAPS) (70). Negative psychotic symptoms were measured with four scales: PANSS (44), 444 
Scale of Assessment of negative symptoms (SANS) (71), CAARMS (2), and the SIPS (3). 445 
Functioning was assessed with five scales, namely the Global Assessment of Functioning 446 
(GAF) (72), the Modified- Global Assessment of Functioning (m-GAF) (73), the Children 447 
Global Assessment Scale (cGAS) (74), the Social and Occupational Functioning Scale 448 
(SOFAS) (75), and the Quality of Life Scale (QLS) (76). Transition to psychosis was 449 
determined with four different transition criteria: CAARMS (five studies, (52,54,60,61,64), 450 
SIPS/SOPS (four studies, (51,59,63,65), PANSS (three studies, (53,55,62), BPRS (two studies, 451 
(56,57), and SCID-1 (one study, (58)) 452 
[Table 2 about here]  453 
Quality assessment of individual CHR-P studies 454 
All CHR-P studies received the maximum score of 4 for assessing the study quality with the 455 
NOS (40): an adequate check that outcome is not present at the start of the study, an adequate 456 
duration of the follow-up period, and an adequate proportion of participants in the follow-up 457 
assessments (see supplement 1 and 2). The three RCTs additionally received an extra point for 458 
blind assessments.   459 
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 460 
Data cleaning and preparation  461 
Missing data and multiple imputations 462 
78,6% of the original sample had data on all variables. There was missing data with regard to 463 
attenuated negative psychotic symptoms (7,2%), functioning (6,6%), attenuated positive 464 
psychotic symptoms (4,8%), CHR-P group (4,2%), age (<0,1%) and sex (<0,1%). 3,8% of the 465 
individuals were omitted from the analyses because of missing of follow-up data. There were 466 
no differences between CHR-P subjects with and without follow-up with regard to age, gender, 467 
type of CHR-P subgroup, attenuated negative psychotic symptoms and functioning at baseline. 468 
Only the severity of attenuated positive psychotic symptoms at baseline was significantly higher 469 
for CHR-P individuals without follow-up (t=-6.244, df=1563, p<.001). 470 
As noted above, the fifteen included CHR-P studies had applied a variety in assessment 471 
instruments with regard to attenuated positive psychotic symptoms, attenuated negative 472 
psychotic symptoms and functioning (see table 1). All measurements were tested as the  core 473 
parameters on the basis of the protocol, yet, although other instruments were applied in more 474 
individuals, attenuated negative psychotic symptoms-total score SIPS, attenuated positive 475 
psychotic symptoms – total score SIPS and GAF were selected because these had the best 476 
predictive performance. SIPS/SOPS is a frequently used instrument in the enclosed studies and 477 
is one of the golden standard measurements for positive and negative psychotic symptoms in 478 
CHR research (77). For functioning, the primary parameter is the frequently applied Global 479 
Assessment of Functioning (GAF) (72). However, because the SIPS were only applied by 480 
18.2% and the GAF by 66.3% of the individuals, there was missing data for 81.8 % (attenuated 481 
positive and negative psychotic symptoms) and 33.7% (functioning). Multiple imputations were 482 
performed with 50 iteration sets. The data from the variables age, gender, GRD, APS, BLIPS, 483 
and functioning (GAF) were used to predict the missing SIPS positive and negative psychotic 484 
symptoms scores. The imputations diagnostics are presented in Supplement III.  485 
Testing collinearity 486 
An overview of the estimated VIFs is presented in Table 3. Overall, the majority of the predictor 487 
variables showed a VIF close to 1, indicating low shared variance with the other variables. 488 
However, the three CHR-P subgroups showed a high level of collinearity. To investigate the 489 
influence of the collinearity, all three predictors were one-by-one subsequently omitted from 490 
the analysis, leading to a drop in VIF scores of below three, yet barely influencing the outcome 491 
of the produced model. Given our aim to develop a prognostic model in which all predictors are 492 
assessed for their relative contribution to risk, these predictors were retained in further analysis, 493 
in line with the methodological recommendations (14). 494 
 495 
[Table 3. about here] 496 
Development and validation of the prognostic model 497 
A parametric survival model with a log-normal distribution is fitted for event times (Royston, 498 
2001): transition to psychosis from a CHR-P stage and time to transition. Supplement V 499 
displays the discriminative performance of the prognostic model in the individual studies at 12 500 
and 24 months. Figure 2 shows a forest plot with the 95%-CI of the Harrell’s C-statistics of the 501 
prognostic model per study and the overall C-statistics.  502 
 [Figure 2 about here]  503 
The C-statistic of the model was 0.655 with the 95%-CI of 0.627 - 0.682 and (approximate) 504 
95% prediction interval of 0.614-0.695. Inspection of the forest plot showed that the prognostic 505 
performance in the larger studies reached an adequate level, with C-statistics of around 0.700 506 
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and 95% CI between 0.54 and 0.87 (52,54,56,57,61,62). This is also visible in the boxplots of 507 
the individual studies (see supplement V): the proportion of predicted survival per risk group is 508 
relatively equal to the observed proportion, meaning that the model can adequately discriminate 509 
between CHR-P individuals with a higher versus lower risk of developing psychosis (1-510 
survival). Yet, smaller studies have lower discriminative adequacy: in the forest plot the 95%-511 
CIs of these studies were broad and included 0.5, which indicated that the model did not 512 
discriminate better than chance.  513 
The calibration slope of the model in the individual CHR-P studies as well as overall 514 
calibration are displayed in Figure 3.  515 
[Figure 3 about here] 516 
The internal-external validation results for the calibration slope gives an overall estimate of 517 
0.886 (95%-CI of 0.745-1.022), which indicated that at 2-year the predicted probabilities, on 518 
average, vary too much. Because the 95%-CI includes 1, the overall calibration slope yields as 519 
non-significant. Calibration slopes of the individual studies not overlapping with 1 indicate no 520 
need for recalibration. Inspection of the forest plot showed that all studies overlapped with 1, 521 
which indicated that the prognostic model calibrates sufficiently well, and there are no direct 522 
indications that the parameters of the model should be adjusted with shrinkage methods.  523 
Final model 524 
Table 4 presents the final model with its intercepts; all included predictors have a significant 525 
contribution to the prediction, as tested with an independent sample T-test. The scale parameter 526 
is 2.119. 527 
[table 4 about here]  528 
Prognostic prediction for individual CHR-P patients 529 
With a parametric survival model with a log-normal distribution for event times, a (cumulative) 530 
survival probability can be calculated for time t in CHR-P individual subjects, utilizing the 531 
linear predictor (5.777) and the earlier reported scale parameter (78).  532 
The following formula that estimates the risk of psychosis (1-survival) for an individual patient 533 
derives from the model:  534 
Risk of psychosis = 1 – (7.543+0.179 (sex=female) + -0.049 x (age)+ .689 x (Genetic Risk and 535 
Deterioration) + -0.370 x (Attenuated Psychotic Symptoms=yes) + -0.738 x (Brief Limited 536 
Intermittent Psychotic Symptoms=yes) + 0.006 x (functioning GAF) + -0.052 x (total score 537 
negative psychotic symptoms SIPS/SOPS) + -0.102 x (total score positive psychotic symptoms 538 
SIPS/SOPS)). 539 
Case study 540 
Considering a 21-years old female that meets the CHR-P criteria of brief intermittent psychotic 541 
symptoms, with baseline GAF score of 65, SIPS/SOPS attenuated negative psychotic symptoms 542 
total score of 13 and a SIPS/SOPS attenuated positive psychotic symptoms total score of 8, the 543 
predicted 2-year survival would be 0.835. This implies that her probability of developing 544 
psychosis within the first 2-year is 1 - .835 = .165, which is of about 16%.  545 
 546 
Heterogeneity  547 
The 95%- prediction interval of the C-statistics (0.614-0.695) shows a moderate range, which 548 
indicates that there is substantial heterogeneity between the predictions of the model in the 549 
different studies. There is a larger amount of heterogeneity detectable with regard to the overall 550 
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calibration slope which shows a rather large 95% CI of 0.745-1.022. This is supported by the 551 
large variety in operationalization of symptoms in the different assessment instruments as well 552 
as variety in outcome criteria.  553 
 554 
DISCUSSION 555 
The aim of this study was to develop and validate a prognostic model based on clinical 556 
predictors that are available in clinical routine for forecasting the onset of a psychotic episode 557 
in CHR-P individuals, using an IPD-MA. The predictors were selected a priori as recommended 558 
by state-of-the-art prognosis guidelines. The predictors encompassed  two demographical 559 
predictors (age, gender) and six clinical predictors collected at baseline (genetic risk and 560 
deterioration syndrome CHR-P subgroup, attenuated psychotic symptoms CHR-P subgroup, 561 
brief and limited intermittent psychotic symptoms CHR-P subgroup, severity of attenuated 562 
positive psychotic symptoms, severity of attenuated negative psychotic symptoms, level of 563 
functioning) predictors. The overall model achieved a C-index of .655, indicating a modest 564 
subject-level ability to differentiate between CHR-P individuals with a high risk likelihood that 565 
develop psychosis from those at lower risk. The overall calibration slope indicated that the 566 
model can significantly distinguish CHR-P individuals who convert to a psychosis versus those 567 
who do not. Most of the included predictors showed a significant contribution to the model, 568 
with the exception of CHR-P group membership (which was characterized by high collinearity). 569 
The removal of these variables from the model indicated that the influence of this collinearity 570 
on the final model was non-significant and minor in magnitude.  571 
This is the first IPD-MA and the largest clinical prediction modelling study conducted in the 572 
CHR-P field. Indeed, one of the main advantages of developing a prognostic model using an 573 
IPD-MA is the possibility of reaching large sample sizes, which enables the building of a more 574 
robust prediction model. Moreover, the model’s generalizability can be strengthened by the 575 
inclusion of several large datasets from all over the world. Ensuring appropriate 576 
representativeness of CHR-P samples is pivotal to developing robust prognostic models because 577 
of the severe sampling biases that affect this population (18,79,80). Our approach was partially 578 
successful. On one side we demonstrated that our a priori selected predictors did produce a 579 
prognostic model that forecasted the onset of psychosis at the individual-subject level with an 580 
accuracy superior to chance (0.655). From a methodological point of view this confirms that 581 
preselecting predictors on the basis of previous knowledge and using all of them in the 582 
prognostic model is a robust way for developing risk prediction algorithms. On the other side, 583 
the level of accuracy was only moderate. This could be due to the fact that our IPD-MA 584 
combined CHR-P studies employing different definitions of predictors and outcomes, and that 585 
there were some missing data (81). Furthermore, in order to ensure a prognostic model that 586 
could easily be applied in clinical practice, we decided to use only one instrument per predictor 587 
(e.g. the SIPS and not the CAARMS, PANSS, SAPS, or BPRS, and the GAF and not the 588 
SOFAS, mGAF, cGAS, or QLS). This was pre-specified at the PROSPERO protocol level. This 589 
decision resulted in missing data which has to be considered as missing not at random (MNAR). 590 
The problem was particularly severe because this led to a rather high level of missing data 591 
(81.8% for the attenuated positive/negative psychotic symptoms and 33.7% for the level of 592 
functioning). Although the missing data were handled with the recommended multiple 593 
imputation techniques (82), it did imbalance the final prognostic model. These choices 594 
counterweight the moderate prognostic accuracy of our model because they facilitate its 595 
theoretical implementability in clinical routine. Scalability of prognostic models is an essential 596 
criterion that should be fully considered beyond the level of prognostic accuracy. In fact, even 597 
prognostic models that have a suboptimal (but clearly higher than random prediction) level of 598 
prognostic performance can be clinically useful if they can enter clinical routine at scale. For 599 
example, a prediction model has recently been developed and validated using a patient data and 600 
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machine-learning to predict treatment outcome in depression: the overall performance of this 601 
model was of a very similar moderate prognostic performance (0.65) (83).  602 
The next stage would be to refine and improve this model. The first option would be to consider 603 
using advanced machine-learning approaches. Yet, there is no strong evidence that these 604 
methods can deliver more robust and implementable prognostic models compared to a priori 605 
defined statistical models. Interestingly, although the prognostic model described above 606 
leveraged machine learning methods, its overall prognostic performance was of a similar level 607 
than that of our current model (83). A recent systematic review conducted by methodologists 608 
showed no performance benefit of machine learning over logistic regression for clinical 609 
prediction models (84). This finding was confirmed by a recent empirical study by our group 610 
(85). However, it is possible that machine learning methods could demonstrate some clear 611 
advantages with the addition of multidimensional predictors encompassing neurobiological, 612 
genetic and other modalities (14). The downside of multimodal approaches is that they tend to 613 
deliver more complex prognostic models at the expenses of scalable implementability. This 614 
IPD-MA study also calls for more homogeneity in the CHR-P assessment instruments or at least 615 
more research in the development of converting formulas. This would have allowed minimizing 616 
missing and imputed data. For example, a between-assessment scale converter algorithm for 617 
symptom rating in schizophrenia has been developed by van Erp et al (86), which enabled both 618 
researchers as clinicians to convert the scores of positive and negative psychotic symptoms 619 
assessed by the PANSS, SANS, and SAPS. Similarly, an automatic Phyton package called 620 
“convert” has been developed to convert CAARMS into SIPS scores and vice versa (36). The 621 
tool is freely available online at https://bitbucket.org/ioppn/convert. Unfortunately, we did not have 622 
the raw data on the specific CAARMS or SIPS (P1-P5) subscales to use this package, but we 623 
only had the overall severity of attenuated positive/negative psychotic symptoms across these 624 
two instruments. Beyond the diversity in the assessment instruments, there is another cause of 625 
suboptimal prognostic performance for our model, which are the baseline intrinsic differences 626 
in study populations. This is supported by the finding that there is substantial diversity in 627 
baseline risks and by the finding that our prognostic model had an adequate level of 628 
performance (C-statistic 0.7) in the subset of the largest CHR-P studies. These studies are likely 629 
to be those with the highest risk enrichment and less affected by sampling biases which are 630 
particularly serious in the case of small CHR-P studies. A meta-analysis by Fusar-Poli et al. 631 
(87) demonstrated that these sampling biases are mostly due to the way CHR-P individuals are 632 
being recruited for undergoing the initial assessment. Specifically, recruiting CHR-P 633 
individuals mostly from the community would dilute the risk enrichment (and therefore the 634 
transition risk) compared to samples mostly recruited through the secondary mental healthcare 635 
system. This was also reflected by the type of outreach campaigns adopted by each CHR-P 636 
clinic. In comparison to CHR-P studies that targeted their outreach campaigns to healthcare 637 
referrers, CHR-P studies with outreach campaigns that were focused on the general public were 638 
associated lower risk of psychosis. There was also a clear relation between the intensity of the 639 
campaign (amount of activities) and a diminished transition risk. In our IPD-MA, CHR-P 640 
studies differed strongly with regard to information campaigns, as well as sources of referrals, 641 
and this factor may have amplified sampling biases and reduced the prognostic performance of 642 
our model.  643 
Another factor that could have modulated the prognostic accuracy of our model may have been 644 
the preventive treatments offered to the CHR-P individuals. An earlier meta-analysis (88) 645 
examined the preventive effects of antipsychotic medication, dietary supplements, integrated 646 
psychological treatments and cognitive behavioural therapy on the transition to psychosis and 647 
reported an overall risk reduction pooled across all of these categories of 54% at 12 months of 648 
54% and of 37% at 24 months. However, the evidence remains inconclusive while a more recent 649 
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network meta-analysis which included about 1,000 more CHR-P individuals found no evidence 650 
to favour specific preventive treatments compared to each other for the prevention of psychosis 651 
(89).  652 
Limitations 653 
One limitation of the current study is that it did not account for treatment effects. The majority 654 
of the included studies have a naturalistic, observational design and as such are an adequate 655 
reflection of current clinical practice. Since subject-level data on preventive interventions was 656 
only available for RCTs (51,54,55), the effects of these treatments could not be entered into the 657 
model, and as such their effects could not be controlled for. However, as indicated above, the 658 
actual effectiveness of preventive treatments for CHR-P individuals is questionable. As such it 659 
is unlikely that this factor would have impacted our findings substantially. Another limitation 660 
is that documented clinical predictors in transition risk could not be used in our model because 661 
these were not recorded in a majority of studies. These predictors are for instance childhood 662 
adversities, cognitive biases, social cognition, verbal fluency, beliefs of social marginalization, 663 
subjective complaints about motor functioning, urbanicity, and poor premorbid social 664 
adjustment. The prediction model could be improved if future studies into risk assessment 665 
would measure these risk factors systematically. The main limitation of this IPD-MA was that 666 
we were only able to collect a minority of the available data. Because of the sampling biases 667 
discussed above, this represents a major barrier to generalizability. It is clear that future IPD-668 
MAs in CHR-P populations face the difficult challenge of collecting all (at least 80%) of 669 
potential studies identified. The additional limitation is that we had to disregard some data 670 
because of the high heterogeneity of the measurements. Future IPD-MA could benefit from the 671 
converting strategies across different scales that have been discussed above here. 672 
Clinical implications 673 
Given the above caveats, implementing the current prediction model in clinical practice is not 674 
desirable. This does not imply that the model is overall redundant. Future refinement of the 675 
model in specific clinical circumstance can be considered. For example, future research can 676 
clarify the characteristics of the largest studies in which this model can perform better. An 677 
answer to this question is rather complex, since these studies vary greatly with regard to 678 
inclusion strategies, with studies accepting self-referrals or referrals by friend or family (52), 679 
studies that screened in help seeking populations (54), as well as specialized secondary care 680 
(57). The offered treatments varied from none (56) to studies with different treatment options 681 
(52,61). Moreover, CAYR (52) shared data of a relatively short follow-up period of only one 682 
year and a transition rate of 9.0%, while FETZ (57) monitored their participants for up to six 683 
years and reported a transition rate of 44.7%.  684 
Further research directions 685 
One avenue for further research could be to investigate whether the prognostic quality of the 686 
current model can be optimized: even though a common reaction is to develop a new prediction 687 
model, the recommendation is to iteratively adjust the model by adding new data (90). The main 688 
reason for updating the available model is the opportunity for further improving the stability 689 
and generalizability of the model by considering additional predictors. Improving the stability 690 
of the current model would result in predicted outcomes less influenced by variation in input 691 
and enhance reliability. This updating can vary between simple recalibration (adjusting the 692 
intercept of the model) or an overall adjustment of the associations of the predictors with the 693 
outcome. The most obvious option for improvement could be found in the inclusion of data 694 
from research projects identified in the systematic search that have not shared their data so far. 695 
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Yet, another possibility is that IPD-MA in CHR-P could never deliver robust prognostic models, 696 
because of the inherited heterogeneity of the underlying population, assessment measurements 697 
and preventive treatments. Such a hypothesis may suggest that future prognostic research in the 698 
CHR-P field should rather focus on conducting new large scale prospective cohort studies that 699 
are well characterized phenotypically.    700 
Conclusion 701 
This is the first IPD-MA in CHR-P individuals and the largest clinical prediction study ever 702 
conducted in these patients to date. 1676 CHR-P individuals have been used to develop and 703 
validate an individualized prognostic model based on clinical variables to forecast transition to 704 
psychosis. The model has a moderate to adequate prognostic accuracy, but there are potential 705 
options to improve its performance. At the same time, it is important to acknowledge that 706 
prognostic models based on IPD-MA may not be particularly effective in the CHR-P field. 707 
Harmonization in the CHR-P assessment instruments is a necessary step towards more 708 
homogenous databases that can support the development and validation of more robust 709 
prognostic models.   710 
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 782 
Contribution to the field 783 
A psychotic disorder emerges mostly in adolescence and early adulthood and affects up to 4 in 784 
100 individuals. The Clinical High Risk state for Psychosis (CHR-P) has become the 785 
cornerstone of modern preventive psychiatry. More recently, individualized prognostic models 786 
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have been used to predict a transition to psychosis, but are typically not easily applicable in 787 
clinical practice, because required information to make a prediction requires specific equipment 788 
or training and is expensive. 789 
In this study, we aimed to build a model to predict who will develop a psychosis based on 790 
information that is routinely collected in the clinical field. For the first time, data from CHR-P 791 
cohort studies worldwide were used to build this model. In this study we show that our model 792 
can moderately predict whether an individual develops psychosis. Despite our positive results, 793 
it is also important to acknowledge some relevant limitations. Because of the large variety 794 
between the CHR-P studies prediction models based on IPD-Mas in this population may not be 795 
able to reach higher performance measures. Harmonization of CHR-P assessments and 796 
therapeutic interventions may be the first step to facilitate future IPD-MAs in this field. 797 
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Table 1. Overview of studies utilized for the development and validation of the prognostic prediction model 
Study  Country Inclusion 
period 
CHR Positive 
psychotic 
symptoms 
Negative 
psychotic 
symptoms 
Functioning  Transition  
criteria 
N  
(% m)  
Age  
(M, SD) 
Follow-
up  
(months) 
Transition 
status at last 
follow-up  
(n, %) 
ADAPT Can 2008-
2010 
SIPS/SOPS SIPS/SOPS SIPS/SOPS GAF SIPS/SOPS 49 
(73.4%) 
21,3 (3,9) 24 3 (6.1%) 
CAYR*  Can 2005-
2014 
CAARMS BPRS SANS GAF CAARMS  176 
(55.7%) 
19,3 (4,0) 12 16 (9.0%) 
DUPS-A  NLD 2002-
2006 
SIPS/SOPS SIPS/SOPS SIPS/SOPS GAF PANSS  69 
(66.7%) 
20,0 (3,7) 36 18 (26.1%) 
EDIE-
NL  
NLD 2008-
2012 
CAARMS CAARMS CAARMS SOFAS CAARMS  195 
(49.2%) 
22,7 (5,4) 18 32 (16.4%) 
EDIE-
UK 
UK 1999-
2002 
PANSS PANSS PANSS GAF PANSS  58 
(68.9%)  
22,2 (4,5)  36  13 (22.4%) 
FePSY* CH 2000-
2015 
BSIP BPRS SANS GAF BPRS  133 
(31.8%) 
24,2 (5,2) 12 - 78 38 (28.8%) 
FETZ  D 1998-
2003 
SIPS/SOPS SIPS/SOPS SIPS/SOPS SOFAS BPRS  161 
(63.3%)  
25,3 (6,1) 12 - 72 72 (44.7%) 
GRAPE KOR 2007-
2011 
SIPS/SOPS SAPS SANS QLS SCID-I 60 
(58.3%) 
19,7 (3,3) 20,7 14 (23.3%) 
INSTEP* JPN 2008-
2013 
SIPS/SOPS PANSS PANSS GAF SIPS/SOPS 53 
(56.6%) 
24,0 (8,4) 36 6 (11.3%) 
OASIS* UK 2013-
2016 
CAARMS CAARMS CAARMS GAF CAARMS  51 
(58.8%) 
22,8 (5,2) 17,7 16 (31.4%) 
PACE AUS 1993-
2006 
CAARMS BPRS SANS GAF CAARMS  415 
(48.2%) 
19,4 (3,4) 12-168 114 (27.7%) 
PORT* POL 2010-
2016 
CAARMS CAARMS CAARMS SOFAS PANSS  107 
(45.8%) 
18,8 (3,5) 12 - 84 20 (18.7%) 
Rome* ITA 2012-
2013 
SIPS/SOPS PANSS PANSS cGAS SIPS/SOPS 19 
(52.6%) 
15,3 (1,3) 12-24 5 (26.3%) 
25 
 
SAFE JPN 2004-
2012 
CAARMS PANSS PANSS GAF CAARMS  106 
(62.3%) 
20,0 (4,4) 28.8 14 (13.2%) 
DUPS-U NLD 2003-
2006 
SIPS/SOPS SIPS/SOPS SIPS/SOPS mGAF SIPS/SOPS  25 
(40.0%) 
16,6 (1,6) 60 7 (28%) 
Abbreviations: AUS: Australia, BPRS: Brief Psychotic Rating Scale, BSIP: Basel Screening Instrument for Psychosis, CAARMS: Comprehensive Assessment 
of At Risk Mental State, CAN: Canada, cGAS: children Global Assessment Scale, CH: Switserland, DSM-IV: Diagnostical and Statistical Manual of mental 
disorders version IV, GAF: Global Assessment of Functioning scale, ITA: Italy, JPN: Japan, KOR: South Korea, m: male, M: mean, mGAF: modified Global 
Assessment of Functioning scale, N: NLD: the Netherlands, PANSS: Positive and Negative Syndrome Scale, POL: Poland, QLS: Quality of Life Scale, SANS: 
Scale for the Assessment of Negative Symptoms, SD: standard deviation, SIPS/SOPS: Structured Interview of Prodromal Symptoms/Scale of Prodromal 
Symptoms, CHR: Ultra High Risk, UK: United Kingdom. 
*Data from the specified study, yet not identical to the data in the published paper, for instance a subsample of the study or sample with a shortened or prolonged 
follow-up then reported in the original paper.  
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Table 2. Summary of study characteristics  
 N 
(studies)  
% of studies % of total sample 
Continent: 
Europe 
Australia 
Northern America  
Asia 
 
9 
1 
2 
3 
 
60.0 
6.7 
13.3 
20.0 
 
48.8 
24.8 
13.4 
13.1 
Design: 
Naturalistic observational 
RCT 
Mixed 
 
11 
3 
1 
 
73.3 
20.0 
6.7 
 
82.0 
18.1 
24.8 
Start inclusion period: 
Before 2000 
2000-2005 
2005-2010 
2010- 
 
3 
4 
5 
3 
 
20.0 
26.7 
33.3 
20.0 
 
37.9 
11.9 
31.9 
10.6 
Inclusion period – duration: 
1 year 
1-2 years 
2-3 years 
>3 years 
 
1 
5 
4 
5 
 
6.7 
33.3 
26.7 
33.3 
 
10.5 
22.3 
17.1 
48.6 
Information campaigns 
Yes 
No 
 
8 
7 
 
53.3 
46.7 
 
50.0 
50.0 
Inclusion strategies 
Referral 
Mixed  
 
12 
3 
 
80.0 
20.0 
 
71.4 
28.6 
Inclusion criteria: in additional to CHR-group: 
Age at inclusion  
A minimum of nine years of education  
No history of antipsychotic medication for over 
16 weeks  
 
10 
1 
 
1 
 
66.7 
6.7 
 
6.7 
 
74.1 
3.6 
 
3.2 
Exclusion criteria: 
Organic cause for prodromal symptoms   
Current or lifetime psychosis  
Intellectual Functioning  
Substance use  
Current or history of antipsychotic medication  
Language requirements  
Diagnosed with pervasive developmental 
disorder or autism spectrum  
A history of electroshock therapy 
Not help seeking individuals  
Suicide risk due to personality disorder  
 
14 
12 
11 
5 
6 
2 
 
2 
1 
1 
1 
 
93.3 
80.0 
73.3 
33.3 
40.0 
13.3 
 
13.3 
6.7 
6.7 
6.7 
 
96.7 
82.9 
67.1 
24.2 
53.8 
19.5 
 
13.7 
3.0 
3.0 
6.3 
Assessment of Ultra high risk: 
SIPS/SOPS 
CAARMS 
PANSS 
 
7 
6 
1 
 
46.7 
40.0 
6.7 
 
26.1 
63.1 
3.5 
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BSIP 1 6.7 7.9 
Assessment of positive psychotic symptoms: 
BPRS 
CAARMS 
SIPS/SOPS 
PANSS 
SAPS 
 
3 
3 
5 
3 
1 
 
20.0 
20.0 
33.3 
20.0 
6.7 
 
43.2 
21.1 
21.1 
13.9 
3.6 
Assessment of negative psychotic symptoms: 
SANS 
PANSS 
SIPS/SOPS 
CAARMS 
 
4 
4 
4 
3 
 
26.7 
26.7 
26.7 
30.0 
 
46.8 
13.6 
18.2 
21.1 
Assessment of functioning: 
GAF 
SOFAS 
mGAF 
cGAS 
QLS 
 
9 
3 
1 
1 
1 
 
60.0 
20.0 
6.7 
6.7 
6.7 
 
66.3 
27.7 
1.5 
1.0 
3.6 
Transition criteria: 
CAARMS 
SIPS/SOPS 
PANSS 
BPRS 
SCID-I 
 
5 
4 
3 
2 
1 
 
46.7 
26.7 
13.3 
13.3 
6.7 
 
56.3 
8.7 
14.0 
17.5 
3.6 
Sample size: 
<50 
50-100 
100-150 
150-200 
>200 
 
3 
5 
3 
3 
1 
 
20.0 
33.3 
20.0 
20.0 
6.7 
 
5.6 
17.4 
20.6 
31.8 
24.7 
Transition rate: 
<10% 
10-20% 
20-30% 
30-40% 
>40% 
 
2 
4 
7 
1 
1 
 
13.3 
26.6 
26.7 
6.7 
6.7 
 
13.4 
27.6 
46.5 
3.0 
9.6 
Treatment: 
CBT (RCT) 
Additional treatment  
None  
 
3 
6 
6 
 
20.0 
40.0 
40.0 
 
18.1 
59.0 
23.1 
 
Abbreviations: BPRS: Brief Psychotic Rating Scale, BSIP: Basel Screening Instrument for Psychosis, CAARMS: 
Comprehensive Assessment of At Risk Mental State, CBT: Cognitive Behavioral Therapy, ,cGAS: children Global Assessment 
Scale, CHR: Clinical High Risk, GAF: Global Assessment of Functioning scale, mGAF: modified Global Assessment of 
Functioning scale, PANSS: Positive and Negative Syndrome Scale, QLS: Quality of Life Scale, RCT: Randomized Controlled 
Trial, SANS: Scale for the Assessment of Negative Symptoms, SCID-I: Structured Clinical Interview for DSM-IV, SIPS/SOPS: 
Structured Interview of Prodromal Symptoms/Scale of Prodromal Symptoms  
Table 3. Predictor variables and accompanying VIF  
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 Dependent 
 Gender Age GRD APS BLIPS Pos Sx Neg Sx Functioning 
In
d
ep
en
d
en
t 
Gender - 1.029 1.028 1.028 1.028 1.028 1.005 1.028 
Age 1.021 - 1.022 1.022 1.020 1.012 1.016 1.022 
GRD 7.857 7.875 - 1.026 1.599 7.877 7.877 7.877 
APS 15.127 15.157 1.975 - 1.790 15.122 15.162 15.142 
BLIPS 9.848 9.848 2.004 1.165 - 9.851 9.870 9.855 
Pos Sx 1.415 1.404 1.419 1.415 1.416 - 1.208 1.418 
Neg Sx 1.833 1.867 1.879 1.879 1.879 1.599 - 1.339 
Functioning 1.586 1.589 1.590 1.588 1.587 1.589 1.133 - 
Abbreviations: APS: Attenuated Psychotic Symptoms, BLIPS: Brief Limited Psychotic 
Symptoms, GRD: Genetic Risk and Deterioration, Sx: Symptoms 
 
Table 4. Variables and intercepts of the final model 
Variable Intercept: T SE of Mean Sign. 95%- confidence interval 
 
Lower Upper 
Intercept 7,543328648      51.792 .14565 <.001 7.251 7.836 
Sex=female 0.179071582     13.247 .01352 <.001 0.152 0.206 
Age -0.048979637      -42.162 .00116 <.001 -0.051 -0.047 
APS=yes -0.369616434  -7.737 .04777 <.001 -0.466 -0.274 
BLIPS=yes -0.738429338      -15.950 .04630 <.001 -0.831 -0.645 
Functioning: GAF 
score 
0.006634737     4.059 .00163 <.001 0.003 0.010 
Negative psychotic 
symptoms: 
SIPS/SOPS-total 
score  
-0.054490819     -14.542 .00375 <.001 -0.062 -0.047 
Positive psychotic 
symptoms: 
SIPS/SOPS-total 
score  
-0.092850985 -16.356 .00574 <.001 -0.105 -0.082 
Abbreviations: APS: Attenuated Psychotic Symptoms, BLIPS: Brief Limited Psychotic 
Symptoms, GRD: Genetic Risk and Deterioration, SE: Standard Error, Sign.: significance 
level, SIPS/SOPS: Structured Interview of Prodromal Symptoms/Scale of Prodromal 
Symptoms 
 
